Barclays
BIOA

Barclays’s BioAge Labs BIOA Stock Holding History

Barclays’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$494K Sell
28,240
-9,540
-25% -$184K ﹤0.01% 3193
2025
Q4 		$500K Buy
37,780
+3,222
+9% +$28.6K ﹤0.01% 3846
2025
Q3 		$203K Sell
34,558
-5,403
-14% -$25.3K ﹤0.01% 4283
2025
Q2 		$165K Buy
39,961
+27,234
+214% +$110K ﹤0.01% 4384
2025
Q1 		$47.9K Sell
12,727
-6,064
-32% -$28K ﹤0.01% 4623
2024
Q4 		$109K Buy
18,791
+6,891
+58% +$119K ﹤0.01% 4574
2024
Q3 		$248K Buy
+11,900
New +$238K ﹤0.01% 4190

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Barclays's BIOA Position: Q1 2026 in Review

Barclays reduced its BioAge Labs (BIOA) stake by 25% in Q1 2026, selling an estimated $184K and leaving 28,240 shares worth $494K. The position accounts for ﹤0.01% of the portfolio, ranked #3193.

Barclays first reported a position in BIOA in Q3 2024 and has held it in 7 quarters since. The position peaked at $500K in Q4 2025. 144 funds tracked by Wall St. Rank hold BIOA as of Q1 2026.

  • Barclays held 28,240 shares of BioAge Labs worth $494K as of Q1 2026.
  • Barclays sold 9,540 BioAge Labs shares in Q1 2026, an estimated $184K.
  • BioAge Labs made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3193 holding.
  • Barclays first reported a position in BioAge Labs in Q3 2024 and has held it in 7 quarters since.
  • Barclays's BioAge Labs position peaked at $500K in Q4 2025.
  • 144 funds tracked by Wall St. Rank held BioAge Labs as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.